Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Overview
Explore Liminatus Pharma, Inc. Class A Common Stock’s financial performance, market position, analyst ratings, and future outlook.
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Key Financials
Key Financials
Market Cap
3.2M
P/E Ratio
-0.26
EPS (TTM)
$-0.25
ROE
2.16%
LIMN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Liminatus Pharma, Inc. Class A Common Stock (LIMN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 36.15, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.26 and a market capitalization of 3.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.